title: Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
abstract: BACKGROUND
  The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.
  
  
  METHODS
  Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.
  
  
  RESULTS
  Fifty-five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36% LAIV vs 33% TIV, P > .999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P < .001), greater seroprotection against influenza A/H1N1 (P = .01), and greater seroconversion against A/H3N2 (P = .004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.
  
  
  CONCLUSIONS
  As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.
  
  
  BACKGROUND
  NCT00906750.
authors.affiliation: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
authors.forename: Silvana
authors.initials: S
authors.lastname: Carr
authors.forename: Kim J
authors.initials: KJ
authors.lastname: Allison
authors.forename: Lee-Ann
authors.initials: LA
authors.lastname: Van De Velde
authors.forename: Kelly
authors.initials: K
authors.lastname: Zhang
authors.forename: Elizabeth Y
authors.initials: EY
authors.lastname: English
authors.forename: Amy
authors.initials: A
authors.lastname: Iverson
authors.forename: Najat C
authors.initials: NC
authors.lastname: Daw
authors.forename: Scott C
authors.initials: SC
authors.lastname: Howard
authors.forename: Fariba
authors.initials: F
authors.lastname: Navid
authors.forename: Carlos
authors.initials: C
authors.lastname: Rodriguez-Galindo
authors.forename: Jie
authors.initials: J
authors.lastname: Yang
authors.forename: Elisabeth E
authors.initials: EE
authors.lastname: Adderson
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: McCullers
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Flynn
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D016867:Immunocompromised Host; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control; D008297:Male; D009369:Neoplasms / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology; D017201:Virus Shedding; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated